Management of Atrial Fibrillation in the Year 2033: NewConcepts, Tools, and Applications Leading to Personalized Medicine

Canadian Journal of Cardiology

Volumn 29, Issue 10, 2013, Pages 1141-1146

  Gillis, Anne M ^a   Krahn, Andrew D ^b   Skanes, Allan C ^c   Nattel, Stanley ^d  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d MONTREAL HEART INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BIOLOGICAL MARKER; HEMOGLOBIN A1C; SOTALOL;

ANTICOAGULATION; BODY SURFACE; CARDIOVASCULAR RISK; CATHETER ABLATION; CEREBROVASCULAR ACCIDENT; EDITORIAL; GENETIC PREDISPOSITION; HEART ATRIUM FIBRILLATION; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; PULMONARY VEIN ISOLATION; QUALITY OF LIFE; RISK ASSESSMENT; THROMBOEMBOLISM;

ATRIAL FIBRILLATION; CANADA; DISEASE MANAGEMENT; HUMANS; INDIVIDUALIZED MEDICINE;

EID: 84884593634     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2013.07.006     Document Type: Editorial

References (48)

1. Go A.S., Hylek E.M., Phillips K.A., et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) Study. JAMA 2001, 285:2370-2375.
2. Lloyd-Jones D.M., Wang T.J., Leip E.P., et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004, 110:1042-1046.
3. Gillis A.M., Skanes A.C. Comparing the 2010 North American and European atrial fibrillation guidelines. Can J Cardiol 2011, 27:7-13.
4. Gillis A.M., Verma A., Talajic M., Nattel S., Dorian P. CCS Atrial Fibrillation Guidelines Committee. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: rate and rhythm management. Can J Cardiol 2011, 27:47-59.
5. Ziegler P.D., Glotzer T.V., Daoud E.G., et al. Detection of previously undiagnosed atrial fibrillation in patients with stroke risk factors and usefulness of continuous monitoring in primary stroke prevention. Am J Cardiol 2012, 110:1309-1314.
6. Daoud E.G., Glotzer T.V., Wyse D.G., et al. Temporal relationship of atrial tachyarrhythmias, cerebrovascular events, and systemic emboli based on stored device data: a subgroup analysis of TRENDS. Heart Rhythm 2011, 8:1416-1423.
7. Healey J.S., Connolly S.J., Gold M.R., et al. Subclinical atrial fibrillation and the risk of stroke. NEngl J Med 2012, 366:120-129.
8. Lubitz S.A., Ellinor P.T. Personalized medicine and atrial fibrillation: will it ever happen?. BMC Med 2012, 10:155.
9. Kapa S., Epstein A.E., Callans D.J., et al. Assessing arrhythmia burden after catheter ablation of atrial fibrillation using an implantable loop recorder: the ABACUS Study. J Cardiovasc Electrophysiol 2013, 24:875-881.
10. Cuculich P.S., Wang Y., Lindsay B.D., et al. Noninvasive characterization of epicardial activation in humans with diverse atrial fibrillation patterns. Circulation 2010, 122:1364-1372.
11. Haissaguerre M., Hocini M., Shah A.J., et al. noninvasive panoramic mapping of human atrial fibrillation mechanisms: a feasibility report. JCardiovasc Electrophysiol 2013, 24:711-717.
12. Guillem M.S., Climent A.M., Millet J., et al. Noninvasive localization of maximal frequency sites of atrial fibrillation by body surface potential mapping. Circ Arrhythm Electrophysiol 2013, 6:294-301.
13. Nattel S. From guidelines to bench: implications of unresolved clinical issues for basic investigations of atrial fibrillation mechanisms. Can J Cardiol 2011, 27:19-26.
14. Benjamin E.J., Chen P.S., Bild D.E., et al. Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop. Circulation 2009, 119:606-618.
15. Wakili R., Voigt N., Kääb S., Dobrev D., Nattel S. Recent advances in the molecular pathophysiology of atrial fibrillation. JClin Invest 2011, 121:2955-2968.
16. Dobrev D., Carlsson L., Nattel S. Novel molecular targets for atrial fibrillation therapy. Nat Rev Drug Discov 2012, 11:275-291.
17. Leong D.P., Delgado V., Bax J.J. Imaging for atrial fibrillation. Curr Probl Cardiol 2012, 37:7-33.
18. Akoum N., Daccarett M., McGann C., et al. Atrial fibrosis helps select the appropriate patient and strategy in catheter ablation of atrial fibrillation: a DE-MRI guided approach. JCardiovasc Electrophysiol 2011, 22:16-22.
19. Lee J.H., Park K.Y., Shin J.H., et al. Symptomatic hemorrhagic transformation and its predictors in acute ischemic stroke with atrial fibrillation. Eur Neurol 2010, 64:193-200.
20. Charidimou A., Shakeshaft C., Werring D.J. Cerebral microbleeds on magnetic resonance imaging and anticoagulant-associated intracerebral hemorrhage risk. Front Neurol 2012, 3:133.
21. Sinha A.M., Diener H.C., Morillo C.A., et al. Cryptogenic Stroke and underlying Atrial Fibrillation (CRYSTAL AF): design and rationale. Am Heart J 2010, 160:36-41.
22. Narayan S.M., Krummen D.E., Shivkumar K., et al. Treatment of atrial fibrillation by the ablation of localized sources: CONFIRM (Conventional Ablation for Atrial Fibrillation With or Without Focal Impulse and Rotor Modulation) trial. JAm Coll Cardiol 2012, 60:628-636.
23. McManus D.D., Lee J., Maitas O., et al. Anovel application for the detection of an irregular pulse using an iPhone 4S in patients with atrial fibrillation. Heart Rhythm 2013, 10:315-319.
24. Verberk W.J., de Leeuw P.W. Accuracy of oscillometric blood pressure monitors for the detection of atrial fibrillation: a systematic review. Expert Rev Med Devices 2012, 9:635-640.
25. Ip J., Waldo A.L., Lip G.Y., et al. Multicenter randomized study of anticoagulation guided by remote rhythm monitoring in patients with implantable cardioverter-defibrillator and CRT-D devices: rationale, design, and clinical characteristics of the initially enrolled cohort The IMPACT study. Am Heart J 2009, 158:364-370.
26. Wyse D.G., Waldo A.L., DiMarco J.P., et al. Acomparison of rate control and rhythm control in patients with atrial fibrillation. NEngl J Med 2002, 347:1825-1833.
27. Roy D., Talajic M., Nattel S., et al. Rhythm control versus rate control for atrial fibrillation and heart failure. NEngl J Med 2008, 358:2667-2677.
28. Cairns J.A., Connolly S., McMurtry S., Stephenson M., Talajic M., CCS Atrial Fibrillation Guidelines Committee Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Can J Cardiol 2011, 27:74-90.
29. Skanes A.C., Healey J.S., Cairns J.A., et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol 2012, 28:125-136.
30. Verma A., Macle L., Cox J., Skanes A.C., CCS Atrial Fibrillation Guidelines Committee Canadian Cardiovascular Society atrial fibrillation guidelines 2010: catheter ablation for atrial fibrillation/atrial flutter. Can J Cardiol 2011, 27:60-66.
31. Natale A. Advances in catheter-ablation treatment of AF. Nat Rev Cardiol 2013, 10:63-64.
32. Pagé P., CCS Atrial Fibrillation Guidelines Committee Canadian Cardiovascular Society atrial fibrillation guidelines 2010: surgical therapy. Can J Cardiol 2011, 27:67-73.
33. Alings M., Smit M.D., Moes M.L., et al. Routine versus aggressive upstream rhythm control for prevention of early atrial fibrillation in heart failure: background, aims and design of the RACE 3 study. Neth Heart J 2013, 21:354-363.
34. Lewalter T., Ibrahim R., Albers B., Camm A.J. An update and current expert opinions on percutaneous left atrial appendage occlusion for stroke prevention in atrial fibrillation. Europace 2013, 15:652-656.
35. Ganesan A.N., Shipp N.J., Brooks A.G., et al. Long-term outcomes of catheter ablation of atrial fibrillation: a systematic review and meta-analysis. JAm Heart Assoc 2013, 2:e004549.
36. Chao T.F., Tsao H.M., Lin Y.J., et al. Clinical outcome of catheter ablation in patients with nonparoxysmal atrial fibrillation: results of 3-year follow-up. Circ Arrhythm Electrophysiol 2012, 5:514-520.
37. Hussein A.A., Saliba W.I., Martin D.O., et al. Natural history and long-term outcomes of ablated atrial fibrillation. Circ Arrhythm Electrophysiol 2011, 4:271-278.
38. Kircher S., Hindricks G., Sommer P. Long-term success and follow-up after atrial fibrillation ablation. Curr Cardiol Rev 2012, 8:354-361.
39. Weerasooriya R., Khairy P., Litalien J., et al. Catheter ablation for atrial fibrillation: are results maintained at 5 years of follow-up?. JAm Coll Cardiol 2011, 57:160-166.
40. Sotomi Y., Inoue K., Ito N., et al. Cause of very late recurrence of atrial fibrillation or flutter after catheter ablation for atrial fibrillation. Am J Cardiol 2013, 111:552-556.
41. Sohns C., Sohns J.M., Vollmann D., et al. Left atrial volumetry from routine diagnostic work up prior to pulmonary vein ablation is a good predictor of freedom from atrial fibrillation. Eur Heart J Cardiovasc Imaging 2013, 14:684-691.
42. Naruse Y., Tada H., Satoh M., et al. Concomitant obstructive sleep apnea increases the recurrence of atrial fibrillation following radiofrequency catheter ablation of atrial fibrillation: clinical impact of continuous positive airway pressure therapy. Heart Rhythm 2013, 10:331-337.
43. Abed H.S., Samuel C.S., Lau D.H., et al. Obesity results in progressive atrial structural and electrical remodeling: implications for atrial fibrillation. Heart Rhythm 2013, 10:90-100.
44. Fein A.S., Shvilkin A., Shah D., et al. Treatment of obstructive sleep apnea reduces the risk of atrial fibrillation recurrence after catheter ablation. J Am Coll Cardiol 2013, 62:300-305.
45. Nademanee K., McKenzie J., Kosar E., et al. Anew approach for catheter ablation of atrial fibrillation: mapping of the electrophysiologic substrate. JAm Coll Cardiol 2004, 43:2044-2053.
46. Narayan S.M., Krummen D.E., Clopton P., Shivkumar K., Miller J.M. Direct or coincidental elimination of stable rotors or focal sources may explain successful atrial fibrillation ablation: on-treatment analysis of the CONFIRM Trial (Conventional Ablation for AF with or without Focal Impulse and Rotor Modulation). JAm Coll Cardiol 2013, 62:138-147.
47. Zou R., Kneller J., Leon L.J., Nattel S. Substrate size as a determinant of fibrillatory activity maintenance in a mathematical model of canine atrium. Am J Physiol Heart Circ Physiol 2005, 289:H1002-H1012.
48. Li D., Fareh S., Leung T.K., Nattel S. Promotion of atrial fibrillation by heart failure in dogs. Atrial remodeling of a different sort. Circulation 1999, 100:87-95.